Profile data is unavailable for this security.
About the company
Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism is to control elevated levels of cortisol (stress hormone) in the brain through the inhibition of the cortisol synthesis enzyme, 11B-HSD1, without affecting production of cortisol by the adrenal glands, which is essential for the body’s normal functioning. Xanamem is a once-a-day pill designed to deliver high levels of cortisol control in key areas of the brain related to Alzheimer’s and other diseases such as the hippocampus and frontal cortex.
- Revenue in AUD (TTM)685.26k
- Net income in AUD-14.73m
- Incorporated1999
- Employees--
- LocationActinogen Medical LtdSelect HouseSE 901 L 9, 109 Pitt StreetSYDNEY 2000AustraliaAUS
- Phone+61 28964-7401
- Fax+61 28964-7588
- Websitehttps://actinogen.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imugene Ltd | 0.00 | -69.02m | 81.99m | 0.00 | -- | 1.24 | -- | -- | -0.3161 | -0.3161 | 0.00 | 0.205 | 0.00 | -- | -- | -- | -58.75 | -48.72 | -75.21 | -53.73 | -- | -- | -- | -- | -- | -- | 0.1913 | -- | -- | -- | 53.89 | -- | 38.40 | -- |
| Alterity Therapeutics Ltd | 446.29k | -12.15m | 87.00m | 9.00 | -- | 1.72 | -- | 194.95 | -0.002 | -0.002 | 0.00007 | 0.0047 | 0.0137 | -- | 5,578.63 | 49,587.78 | -37.23 | -49.00 | -43.12 | -57.35 | -- | -- | -2,721.96 | -9,708.51 | -- | -211.82 | 0.0037 | -- | 66.27 | 91.97 | 36.48 | -- | -- | -- |
| Cynata Therapeutics Ltd | 227.70k | -9.39m | 87.86m | 0.00 | -- | 13.98 | -- | 385.85 | -0.0453 | -0.0453 | 0.0011 | 0.0265 | 0.0292 | -- | 2.16 | -- | -120.50 | -48.36 | -142.29 | -53.09 | -- | -- | -4,124.10 | -576.20 | -- | -1,268.00 | 0.00 | -- | -45.49 | 28.12 | 3.63 | -- | -- | -- |
| LTR Pharma Ltd | 2.10m | -5.59m | 93.62m | -- | -- | 2.96 | -- | 44.50 | -0.0333 | -0.0333 | 0.0126 | 0.1741 | 0.1183 | -- | 8.22 | -- | -31.44 | -- | -32.47 | -- | -- | -- | -265.90 | -- | 45.76 | -62.54 | 0.00 | -- | 4,164.38 | -- | 19.57 | -- | -- | -- |
| Tetratherix Ltd | 1.14m | -9.43m | 100.55m | -- | -- | 6.83 | -- | 88.00 | -0.1873 | -0.1873 | 0.0227 | 0.5414 | 0.0688 | -- | 2.22 | -- | -56.71 | -- | -76.72 | -- | -172.06 | -- | -824.89 | -- | -- | -98.75 | 0.0697 | -- | 32.30 | -- | -269.05 | -- | -- | -- |
| Island Pharmaceuticals Ltd | 58.80k | -3.92m | 103.59m | -- | -- | 12.70 | -- | 1,761.65 | -0.0224 | -0.0224 | 0.0003 | 0.0303 | 0.0117 | -- | 0.1099 | -- | -77.95 | -72.12 | -90.37 | -81.53 | -- | -- | -6,666.91 | -19,239.15 | -- | -162.89 | 0.00 | -- | 1,148.41 | -- | -36.86 | -- | -- | -- |
| Bioxyne Ltd | 28.43m | 4.90m | 107.52m | 16.00 | 20.69 | 8.37 | 18.90 | 3.78 | 0.0023 | 0.0023 | 0.0132 | 0.0057 | 2.16 | 6.30 | 17.06 | -- | 37.31 | -28.17 | 55.76 | -38.16 | 36.32 | 35.97 | 17.24 | -24.14 | 1.90 | -- | 0.1125 | -- | 204.87 | 65.94 | 138.29 | -- | 127.89 | -- |
| Arovella Therapeutics Ltd | 525.53k | -7.51m | 111.71m | 14.00 | -- | 5.51 | -- | 212.57 | -0.0067 | -0.0067 | 0.0005 | 0.0169 | 0.0301 | -- | -- | -- | -43.05 | -75.94 | -47.90 | -90.89 | -- | -- | -1,428.87 | -2,386.13 | -- | -- | 0.00 | -- | 237.44 | -1.82 | 14.14 | -- | 1.23 | -- |
| Paradigm Biopharmaceuticals Ltd | 7.11m | -18.77m | 130.10m | -- | -- | 5.51 | -- | 18.31 | -0.047 | -0.047 | 0.0183 | 0.0544 | 0.2684 | -- | 1.14 | -- | -70.91 | -67.55 | -80.99 | -75.98 | 99.71 | 99.24 | -264.18 | -527.01 | -- | -9,722.29 | 0.0003 | -- | 10.29 | 8.87 | 68.04 | -- | -- | -- |
| Actinogen Medical Ltd | 685.26k | -14.73m | 141.93m | -- | -- | 7.10 | -- | 207.12 | -0.005 | -0.005 | 0.0002 | 0.0058 | 0.0299 | -- | 0.0907 | -- | -64.34 | -53.87 | -76.58 | -59.25 | -- | -- | -2,149.88 | -3,680.96 | -- | -231.81 | 0.1511 | -- | 135.46 | 48.76 | -12.94 | -- | 10.81 | -- |
| Nyrada Inc | 2.56m | -4.85m | 193.51m | -- | -- | 46.58 | -- | 75.63 | -0.0243 | -0.0243 | 0.0128 | 0.017 | 0.4566 | -- | -- | -- | -86.47 | -48.87 | -112.02 | -53.88 | -- | -- | -189.37 | -195.83 | -- | -- | 0.00 | -- | -24.81 | 18.93 | -248.28 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 19 May 2025 | 198.24m | 6.21% |
| Pengana Capital Ltd.as of 31 Oct 2025 | 46.67m | 1.46% |
